Resources from the same session
1MO - The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study
Presenter: Zhimin Shao
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
2MO - Final analysis of the phase III randomized clinical trial, comparing HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting
Presenter: Xavier Pivot
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 1MO and 2MO
Presenter: Ching-Hung Lin
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Khalil Zaman
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
3MO - Patient-reported outcomes (PROs) of Chinese patients (pts) in monarchE: Abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
Presenter: Qingyuan Zhang
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
21MO - Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2– ABC
Presenter: Zhimin Shao
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
22MO - Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial
Presenter: Fei Ma
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 3MO, 21MO and 22MO
Presenter: Soo Chin Lee
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Khalil Zaman
Session: Mini Oral session: Breast cancer
Resources:
Slides
Webcast
4MO - Prognostic implication of 21-gene expression assay in luminal B type hormone receptor-positive breast cancer patients younger than 40 years
Presenter: Jaewon Hyung
Session: Mini Oral session: Breast cancer
Resources:
Abstract
Slides
Webcast